Oncolytics Biotech Inc.
4660 La Jolla Village Drive
Suite 850
San Diego
CA
92122
United States
Website: http://www.oncolyticsbiotech.com/
499 articles about Oncolytics Biotech Inc.
-
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board
10/19/2020
Oncolytics Biotech® Inc. announced the appointment of Richard Vile, Ph.D., to its Scientific Advisory Board.
-
Oncolytics Biotech® to Participate in BIO Investor Forum Digital
10/7/2020
Oncolytics Biotech® Inc. announced that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020.
-
Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences
9/1/2020
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will be presenting a corporate overview at the following investor conferences in September
-
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
8/26/2020
Oncolytics Biotech® Inc. announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer.
-
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference
8/10/2020
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the Canaccord Genuity 40th Annual Growth Conference.
-
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
8/4/2020
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended June 30, 2020.
-
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
7/29/2020
- Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at 4:30 pm ET to discuss a corporate update and financial results for the second quarter of 2020.
-
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
6/25/2020
Multi-center trial to evaluate the safety and efficacy of pelareorep-anti-PD-1 combination therapy in triple-negative breast cancer, an indication of continued unmet medical need
-
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
6/23/2020
Study will evaluate pelareorep's ability to synergistically combine with the checkpoint inhibitor therapy avelumab and improve outcomes in metastatic breast cancer
-
Oncolytics Biotech® Establishes New At-The-Market Facility
6/16/2020
Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that it has entered into an at-the-market equity offering sales agreement with Canaccord Genuity LLC.
-
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
6/4/2020
Recently announced clinical data demonstrate pelareorep-induced priming of an adaptive immune response
-
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
5/29/2020
Combination therapy with pelareorep activates a profound inflammatory response
-
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
5/26/2020
Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced the publication of an electronic-poster with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.
-
Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
5/14/2020
Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple myeloma patients treated with pelareorep and carfilzomib
-
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
5/13/2020
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey , President & CEO of Oncolytics Biotech, will present during the RBC Global Healthcare Conference at 1:55 pm Eastern Time on Wednesday , May 20
-
Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
5/8/2020
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020 . All dollar amounts are expressed in Canadian currency unless otherwise noted.
-
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
5/8/2020
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020.
-
Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
5/4/2020
AWARE-1 data demonstrate pelareorep-mediated priming of an adaptive immune response
-
Oncolytics Biotech® Announces Changes to Annual General Meeting in May 7, 2020.
4/30/2020
Oncolytics Biotech® Inc., announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting to be held at 4:30 p.m. on May 7, 2020..
-
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
4/17/2020
Oncolytics Biotech® Inc. provided an update on the potential impact of COVID-19 on the Company's clinical and business operations.